Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p <...
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.01 | 11.0865968009 | 18.13 | 20.5 | 17.06 | 2169767 | 19.04760015 | CS |
| 4 | -1.76 | -8.03652968037 | 21.9 | 23.65 | 17.06 | 1800366 | 19.92443527 | CS |
| 12 | -4.145 | -17.0681490632 | 24.285 | 27.2 | 17.06 | 1227874 | 21.37657155 | CS |
| 26 | 7.42 | 58.3333333333 | 12.72 | 27.2 | 11.85 | 1345047 | 19.22375688 | CS |
| 52 | -2.81 | -12.2440087146 | 22.95 | 27.2 | 11.4 | 1153345 | 18.20691974 | CS |
| 156 | -1.38 | -6.4126394052 | 21.52 | 39 | 9.47 | 759137 | 19.83635334 | CS |
| 260 | -1.25 | -5.84385226741 | 21.39 | 39 | 9.47 | 602510 | 19.66508765 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
